FDA approves Vosevi for Hepatitis C

SILVER SPRING, Md., July 18, 2017 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Vosevi to treat adults with chronic hepatitis C virus (HCV) genotypes 1-6 without cirrhosis (liver disease) or with mild cirrhosis. Vosevi is a fixed-dose, combination tablet...